Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 5, 2022

UNION therapeutics begins enrolment in trial of orismilast for psoriasis

The Phase IIb study will assess orismilast’s safety and efficacy in patients with moderate to severe plaque psoriasis.

By Hasini Devarasetti

UNION therapeutics has enrolled the first participant in the IASOS Phase IIb study of oral orismilast in psoriasis patients.

The latest move comes after the company received Investigational New Drug Program (IND) approval from the US Food and Drug Administration (FDA) in November 2020 to advance orismilast into a Phase IIb study.

With broad anti-inflammatory properties, orismilast is a next-generation phosphodiesterase type-4 (PDE4) inhibitor.

It has been developed as a modified release (MR) tablet to reduce gastrointestinal side effects occurrence.

The double-blind, placebo-controlled, randomised, parallel-group, dose-ranging Phase IIb study will assess orismilast’s safety and efficacy in moderate to severe plaque psoriasis patients.

In this study, approximately 200 participants will be recruited and randomised to receive three active doses of orismilast and a placebo administered twice-daily.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

It will be conducted in nearly 40 trial sites in North America and Europe.

The safety and efficacy of a modified release orismilast tablet versus placebo will be evaluated as the trial’s primary goal.

UNION therapeutics CEO Kim Kjøller said: “Orismilast holds the potential to be a best-in-class treatment and game-changer for psoriasis patients.

“With the first patient enrolled in the Phase IIb study in psoriasis, we are one step closer to offering psoriasis patients a novel oral treatment option.”

The IASOS study aims to identify the appropriate dose regimen of oral orismilast for Phase III studies.

Furthermore, orismilast is in development to treat atopic dermatitis (AD) and hidradenitis suppurativa (HS).

Last April, UNION therapeutics reported that its inhaled and intranasal niclosamide (UNI91103 and UNI91104) showed a strong safety profile in a Phase I study.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU